ShockWave Medical, Inc. (NASDAQ: SWAV) closed at USD 334.75, slightly down by 0.08 (-0.0239%) from its previous session, following a surge in trading activity that pushed volumes well above the company’s average. This update reflects recent price movement and provides investors with a detailed profile of the company’s operational and market context.
In this article:
- Company overview
- Stock performance
- Market position and sector
- Governance and leadership
- Key financial data
- FAQ
- Conclusion
- Disclaimer
- Official company source
Company overview
ShockWave Medical, Inc. develops and markets proprietary intravascular lithotripsy technology aimed at the treatment of calcified plaque in cardiovascular diseases. Its products include M5 catheters for above-the-knee peripheral artery disease, C2 catheters for coronary artery disease, and S4 catheters for below-the-knee cases. The company serves interventional cardiologists, vascular surgeons, and interventional radiologists with support from sales representatives, managers, and distribution partners. Founded in 2009, ShockWave Medical is headquartered in Santa Clara, California.
With a strong focus on innovation in the Medical Devices segment, ShockWave Medical operates at the intersection of advanced engineering and critical healthcare delivery.
Stock performance
As of the latest trading session, SWAV shares settled at USD 334.75. This marks a minor daily decline of 0.08 points, equivalent to -0.0239%. Despite this marginal drop, the price stands near the upper bound of its 52-week range (USD 157.0 – USD 334.9), indicating robust growth from earlier lows.
Trading volume reached 3,947,054 shares, substantially exceeding the average daily volume of 1,301,576. Elevated volume levels often point to intensified market interest or reaction to news, possibly impacting short-term volatility.
Market position and sector
ShockWave Medical sits within the Healthcare sector and specifically in Medical Devices, a segment driven by technological advancement and regulatory oversight. The device market benefits from increasing demand for minimally invasive procedures, an aging population, and the ongoing innovation pipeline.
With a market capitalization of approximately USD 12.57 billion, the company holds a substantial position among mid-to-large cap medical device manufacturers. Its market standing offers potential visibility among institutional investors and inclusion in sector-specific indices.
Governance and leadership
Douglas E. Godshall serves as Chief Executive Officer, guiding corporate strategy and product development. Under his leadership, the company has expanded its product portfolio and grown market penetration. Experienced governance and operational leadership are critical in a regulated industry where compliance and quality assurance shape reputational and financial outcomes.
The company employs 1,468 full-time staff, reflecting a balanced scale for a specialized medical device firm with global ambitions.
Key financial data
Trading details
- Exchange: NASDAQ Global Select
- Ticker: SWAV
- ISIN: US82489T1043
- CUSIP: 82489T104
- IPO Date: March 7, 2019
- Currency: USD
Financial indicators
- Price: USD 334.75
- Market Cap: USD 12,567,686,625
- 52-week range: USD 157.0 – USD 334.9
- Volume: 3,947,054 shares
- Average Volume: 1,301,576 shares
- Dividend: No dividend declared
The absence of a dividend signals a reinvestment focus, common among growth-oriented device manufacturers. High market cap supports liquidity, but considerable volume can amplify short-term price swings. Investors often consider range data to evaluate resistance and support levels.
FAQ
- Does ShockWave Medical pay dividends? Currently, the company reports no dividend distribution.
- Where is the company headquartered? Santa Clara, California, US.
- On which exchange does SWAV trade? NASDAQ Global Select Market.
- What is the employee count? 1,468 full-time employees.
- What is the primary industry? Medical Devices within the Healthcare sector.
Conclusion
ShockWave Medical’s stock remains at the higher end of its annual performance range with a market capitalization above USD 12.5 billion. The company continues to leverage its technology leadership in medical devices. Recent trading spikes may draw investor attention, leading to potential short-term fluctuations. Long-term prospects rest on sustained innovation and regulatory compliance.
Disclaimer
This article is provided for informational purposes only and does not constitute financial advice. Readers should perform their own due diligence before making investment decisions.
Official company source
For full information about the company, see the link below.